Home > Publications database > From class waivers to precision medicine in paediatric oncology. > print

001     125219
005     20240228145518.0
024 7 _ |a 10.1016/S1470-2045(17)30442-4
|2 doi
024 7 _ |a pmid:28677575
|2 pmid
024 7 _ |a 1470-2045
|2 ISSN
024 7 _ |a 1474-5488
|2 ISSN
024 7 _ |a altmetric:21401267
|2 altmetric
037 _ _ |a DKFZ-2017-01374
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Pearson, Andrew D J
|b 0
245 _ _ |a From class waivers to precision medicine in paediatric oncology.
260 _ _ |a London
|c 2017
|b The Lancet Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1533036490_1957
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively searched oncology drugs that were class waivered between June, 2012, and June, 2015. 147 oncology class waivers were confirmed for 89 drugs. Mechanisms of action were then assessed as potential paediatric therapeutic targets by both a literature search and an expert review. 48 (54%) of the 89 class-waivered drugs had a mechanisms of action warranting paediatric development. Two (2%) class-waivered drugs were considered not relevant and 16 (18%) required further data. In light of these results, we propose five initiatives: an aggregated database of paediatric biological tumour drug targets; molecular profiling of all paediatric tumours at diagnosis and relapse; a joint academic-pharmaceutical industry preclinical platform to help analyse the activity of new drugs (Innovative Therapy for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform); paediatric strategy forums; and the suppression of article 11b of the European Paediatric Regulation, which allows product-specific waivers on the grounds that the associated condition does not occur in children. These initiatives and a mechanism of action-based approach to drug development will accelerate the delivery of new therapeutic drugs for front-line therapy for those children who have unmet medical needs.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 1
700 1 _ |a Baruchel, Andre
|b 2
700 1 _ |a Bourquin, Jean-Pierre
|b 3
700 1 _ |a Casanova, Michela
|b 4
700 1 _ |a Chesler, Louis
|b 5
700 1 _ |a Doz, François
|b 6
700 1 _ |a Eggert, Angelika
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Geoerger, Birgit
|b 8
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 9
700 1 _ |a Kearns, Pamela R
|b 10
700 1 _ |a Molenaar, Jan J
|b 11
700 1 _ |a Morland, Bruce
|b 12
700 1 _ |a Schleiermacher, Gudrun
|b 13
700 1 _ |a Schulte, Johannes
|0 P:(DE-He78)91317a47fc8532e3daf0d0b362c2a27e
|b 14
700 1 _ |a Vormoor, Josef
|b 15
700 1 _ |a Marshall, Lynley V
|b 16
700 1 _ |a Zwaan, C Michel
|b 17
700 1 _ |a Vassal, Gilles
|b 18
700 1 _ |a Consortium, Executive and Biology Committees of the Innovative Therapies for Children with Cancer European
|b 19
|e Collaboration Author
773 _ _ |a 10.1016/S1470-2045(17)30442-4
|g Vol. 18, no. 7, p. e394 - e404
|0 PERI:(DE-600)2035574-9
|n 7
|p e394 - e404
|t The @lancet / Oncology
|v 18
|y 2017
|x 1470-2045
909 C O |p VDB
|o oai:inrepo02.dkfz.de:125219
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)91317a47fc8532e3daf0d0b362c2a27e
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET ONCOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 25
|0 StatID:(DE-HGF)9925
|2 StatID
|b LANCET ONCOL : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)L201-20160331
|k L201
|l DKTK Berlin
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)L201-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21